MedTrace Logo

Presepsin in the Diagnosis of Sepsis in Critically Ill Patients

NCT03584594 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2022-12-07

No results posted yet for this study

Summary

Sepsis is one of the most common causes of death worldwide. It is caused by a complex of inadequate host responses to infection. Sepsis remains a major challenge of modern intensive care medicine. Despite recent improvements, the incidence of sepsis in critically ill patients increases steadily (25%) and mortality rates remain unacceptably high (30%). It is difficult to distinguish the sepsis from the non-infectious systemic inflammatory response syndrome. Early identification of the origin of infection can help dramatically to improve outcome and reduce mortality. That is why clinicians need fast, reliable and specific biomarkers for sepsis recognition.

Conditions

Interventions

DIAGNOSTIC_TEST

Presepsin measurement

Presepsin measurements are performed with PathFast immunoassay analytical system on the ICU, bedside method. (Mitsubishi Chemical, Japan).

Sponsors & Collaborators

  • Public Health Institute Ostrava

    collaborator UNKNOWN

  • University Hospital Ostrava

    lead OTHER

Principal Investigators

  • Marcela Káňová, MD,Ph.D. · University Hospital Ostrava

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2021-12-31
Completion
2022-03-30

Countries

  • Czechia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03584594 on ClinicalTrials.gov